



ASX Release  
12 May 2020

ASX Code: MEM

### Expanded trading in Germany

Australian-based bio-separations company Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to advise that exposure to investors in the European market has expanded, through its listing on a range of prominent local exchanges, which has led to an increase in trading of MEM securities in Germany.

“In the past few months, we noticed an increase in demand of Memphasys shares in the German-speaking region through a secondary listing at the “open market” of the Frankfurt Stock Exchange. The listing on the additional exchanges was driven by local investor demand, which has increased in recent weeks,” said Memphasys Executive Chairman, Alison Coutts.

In addition to its “open market” listing on the Frankfurt Stock Exchange, Memphasys has recently been listed for trading on the “open market” Berlin, Munich and Stuttgart Stock Exchanges. It is also now listed for trading on the Berlin based Tradegate Exchange.

Memphasys is focused on the development and commercialisation of the Felix device – a unique device for quickly separating high quality sperm from a semen sample for use in human IVF procedures.

It is currently in the pre-commercialisation phase, with first sales expected in late 2020.

This announcement has been approved for release by the board of Memphasys Limited.

ENDS

#### For further information please contact:

Alison Coutts  
Executive Chairman  
Memphasys Limited  
T: +61 2 8415 7300  
E: [alison.coutts@memphasys.com](mailto:alison.coutts@memphasys.com)

David Tasker  
Managing Director  
Chapter One Advisors  
T: +0433 112 936  
E: [dtasker@chapteroneadvisors.com.au](mailto:dtasker@chapteroneadvisors.com.au)

#### About Memphasys:

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.

Website: [www.memphasys.com](http://www.memphasys.com)